Levetiracetam-induced interstitial lung disease in a patient with advanced lung cancer.
AED, antiepileptic drug
BALF, bronchoalveolar lavage fluid
Drug-induced interstitial lung disease
EGFR, epidermal growth factor receptor
GGO, ground-glass opacity
ILD, interstitial lung disease
LEV, levetiracetam
Levetiracetam
Lung cancer
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
04
2020
revised:
27
08
2020
accepted:
12
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
An 85-year-old woman with antibiotics-resistant pneumonia after surgery for metastatic brain tumor from lung cancer was consulted to our department. Chest CT showed diffuse GGO bilaterally. BALF showed elevated ratios of lymphocytes and CD4/CD8. Tests for bacteria, mycobacteria, and fungi were negative. She improved following levetiracetam discontinuance and systemic corticosteroid administration, and we diagnosed levetiracetam-induced lung injury. Although levetiracetam is widely used, few reports of levetiracetam-induced pneumonia exist. Changes in chest images may occur after levetiracetam administration if patients have multiple risk factors for development of drug-induced interstitial lung disease. Bronchoscopy is useful for differential diagnosis if new lung lesions appear after starting levetiracetam.
Identifiants
pubmed: 33024691
doi: 10.1016/j.rmcr.2020.101241
pii: S2213-0071(20)30455-X
pmc: PMC7528199
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101241Informations de copyright
© 2020 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare no Conflicts of Interest (COI) in association with this article.
Références
Med Clin (Barc). 2007 Feb 10;128(5):198-9
pubmed: 17298785
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Neurooncol Pract. 2016 Dec;3(4):245-260
pubmed: 31385988
Chest. 1997 Dec;112(6):1697-9
pubmed: 9404778
Epilepsy Behav. 2017 Apr;69:186-222
pubmed: 28237319
Respir Med Case Rep. 2019 Aug 11;28:100922
pubmed: 31463188
Rev Mal Respir. 1998 Dec;15(6):797-9
pubmed: 9923035
Curr Neuropharmacol. 2012 Jun;10(2):124-33
pubmed: 23204982
J Neurooncol. 2010 Jan;96(1):97-102
pubmed: 19957015
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007286
pubmed: 23450575
Oncologist. 2014 Jul;19(7):751-9
pubmed: 24899645
Neurosurg Rev. 2020 Apr;43(2):709-718
pubmed: 31098789
J Neurooncol. 2012 May;108(1):109-14
pubmed: 22311106
Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-23
pubmed: 18830435
BMJ Case Rep. 2016 Jan 29;2016:
pubmed: 26825933
J Clin Med. 2018 Oct 15;7(10):
pubmed: 30326612
Neurology. 2000 May 23;54(10):1886-93
pubmed: 10822423
Nihon Kokyuki Gakkai Zasshi. 2009 Aug;47(8):758-62
pubmed: 19764523
BMJ Case Rep. 2009;2009:bcr2006063842
pubmed: 21687090
Neurosurgery. 2019 Mar 1;84(3):E195-E197
pubmed: 30629248
Postgrad Med J. 2002 Oct;78(924):621-2
pubmed: 12415089
J Neurosurg. 2018 Sep 21;131(3):936-940
pubmed: 30239312
Mayo Clin Proc. 1997 Dec;72(12):1145-7
pubmed: 9413295
Acta Derm Venereol. 2015 Feb;95(2):229-30
pubmed: 24696158
Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61
pubmed: 19499221
BMJ Case Rep. 2017 Mar 8;2017:
pubmed: 28275024
Neurology. 2000 Jul 25;55(2):236-42
pubmed: 10908898
Nihon Kokyuki Gakkai Zasshi. 2005 Mar;43(3):150-4
pubmed: 15801283
Pharmacol Ther. 2000 Feb;85(2):77-85
pubmed: 10722121
Biomed Res Int. 2019 Sep 24;2019:7863815
pubmed: 31662996